☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
emdac
The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes
May 28, 2021
Boehringer Ingelheim and Lilly Report FDA's EMDAC Outcomes for Empagliflozin (2.5mg) as Adjunct to Insulin for T1D Patients
November 14, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.